Vivacelle Bio
PrivateLast Round
Series B
Feb 22, 2024
Total Funding Raised
$20.95M
Company Overview
Vivacelle Bio operates in Healthcare & Life Sciences and is based in Kansas City, Missouri. Its latest recorded funding round was a Grant round in September 2021.
Vivacelle Bio is a biotechnology company that develops nanoparticle-based resuscitation fluid therapies designed to treat septic shock and severe blood loss.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivacelle Bio Comparables
Compare Vivacelle Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adrenomed AG | 77% | |
| Matisse Pharmaceuticals | 75% | |
| Perfusion Medical | 74% |
For institutional investors. Book with your work email.
Vivacelle Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 22, 2024 | ||||
| Grant | Sep 7, 2021 | ||||
| Grant | Nov 24, 2020 | ||||
| Series A | Jan 11, 2019 | ||||
| Seed | Sep 3, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vivacelle Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant, Seed |
| U.S. Department of War | Seed, Grant |
| 2Flo Ventures | Seed, Series A |
| Medical Technology Enterprise Consortium | Grant |
| U.S. Navy | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors increased 50% MoM, reaching 1.2K.
- Jan 13, 2025
Attending BIO Partnering @ JPM Week 2025 in San Francisco.
For institutional investors. Book with your work email.
Vivacelle Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vivacelle Bio's valuation, stock price, and market status.
Is Vivacelle Bio a public or private company?
Vivacelle Bio is a private company.
What is the current stock price of Vivacelle Bio?
Vivacelle Bio is a private company, so its shares have no public market price. Caplight tracks Vivacelle Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vivacelle Bio worth (valuation)?
Valuation information for Vivacelle Bio is not publicly available.
Can I buy Vivacelle Bio stock?
Vivacelle Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vivacelle Bio's last funding round?
Vivacelle Bio's most recent funding round was Series B on February 22, 2024.
Who are the main investors in Vivacelle Bio?
Key investors in Vivacelle Bio include NIH RADx, U.S. Department of War, 2Flo Ventures, Medical Technology Enterprise Consortium, U.S. Navy.
Will Vivacelle Bio IPO soon?
No public IPO plans have been announced for Vivacelle Bio.
How can I track Vivacelle Bio secondary market activity?
Caplight tracks bids, offers, and trades in Vivacelle Bio's shares on secondary markets.